» Articles » PMID: 12643006

Radiation-induced Mucositis: a Randomized Clinical Trial of Micronized Sucralfate Versus Salt & Soda Mouthwashes

Overview
Journal Cancer Invest
Specialty Oncology
Date 2003 Mar 20
PMID 12643006
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Oral mucositis is one of the major toxicities caused by radiation therapy (RT) treatments to the head and neck. The clinical efficacy of sucralfate (Carafate R) mouthwash for head and neck cancer patients (HNC) is not consistent across studies. In this study, it was hypothesized that if the particles in the original sucralfate suspension were micronized (i.e., < or = 25 microns) then the coating action of the mouthwash in the oral cavity would be enhanced. The purpose of this pilot study was to compare the efficacy of micronized sucralfate (Carafate R) mouthwash and salt & soda mouthwash in terms of the severity of the mucositis, the severity of mucositis-related pain, and the time required to heal RT-induced mucositis in patients with HNC. Severe mucositis and related pain can interfere with the ingestion of food and fluids, so patients' body weights were measured as well. All patients in this randomized clinical trial carried out a systematic oral hygiene protocol called the PRO-SELF: Mouth Aware (PSMA) Program. Patients who developed RT-induced mucositis anytime during their course of RT were randomized to one of the two mouthwashes and followed to the completion of RT and at one month following RT. Two referral sites were used for the study. Repeated measures occurred with the following instruments/variables: MacDibbs Mouth Assessment and weight. Demographic, disease, and cancer treatment information was also obtained. Thirty patients successfully completed the study. The typical participant was male (70%), married/partnered (70%), White (63%), not working or retired (73%), and had an average of 14.5 years of education (SD = 3.7). T-tests and Chi-square analyses with an alpha set at 0.05 were used to compare differences between the two mouthwashes. No significant differences were found in the number of days to onset of mucositis (i.e., 16 +/- 8.4 days). When patients had their worst MacDibbs score, (i.e., the most severe mucositis), there were no significant differences between the mouthwashes as to MacDibbs score, the RT dose received, or ratings of pain (upon swallowing). Similarly, at the end of RT, no significant differences were found between mouthwashes as to MacDibbs scores or ratings of pain (upon swallowing). At the one-month follow-up assessment no significant differences were found between the mouthwashes in MacDibbs scores or pain ratings (upon swallowing). The analysis of the efficacy of the two mouthwashes revealed no significant differences in the time to heal (in days) from the RT-induced mucositis. The findings from this trial provide important clinical information regarding cost analysis of RT mucositis management. Given that there is no significant difference in efficacy between micronized sucralfate and salt & soda, use of the less costly salt & soda is prudent and cost-effective.

Citing Articles

Prevention and the treatment of oral mucositis: the efficacy of sodium bicarbonate vs other agents: a systematic review.

Di Fede O, Canepa F, Maniscalco L, Tozzo P, Matranga D, Giuliana G BMC Oral Health. 2023; 23(1):4.

PMID: 36597048 PMC: 9811717. DOI: 10.1186/s12903-022-02586-4.


Potential therapeutic effects of different mouthwashes for alleviation and treatment of oral complications of 5-fluorouracil-based chemotherapy in patients with colon cancer.

Al-Taie A, Koseoglu A Eur J Hosp Pharm. 2021; 30(4):202-207.

PMID: 34285108 PMC: 10359790. DOI: 10.1136/ejhpharm-2021-002827.


Status of Treatment and Prophylaxis for Radiation-Induced Oral Mucositis in Patients With Head and Neck Cancer.

Liu S, Zhao Q, Zheng Z, Liu Z, Meng L, Dong L Front Oncol. 2021; 11:642575.

PMID: 33816293 PMC: 8013721. DOI: 10.3389/fonc.2021.642575.


Current topical trends and novel therapeutic approaches and delivery systems for oral mucositis management.

Al-Taie A, Al-Shohani A, Albasry Z, Altaee A J Pharm Bioallied Sci. 2020; 12(2):94-101.

PMID: 32742107 PMC: 7373116. DOI: 10.4103/jpbs.JPBS_198_19.


Topical Treatment of Oral Mucositis in Cancer Patients: A Systematic Review of Randomized Clinical Trials.

Sant Ana G, Normando A, De Toledo I, Reis P, Guerra E Asian Pac J Cancer Prev. 2020; 21(7):1851-1866.

PMID: 32711408 PMC: 7573410. DOI: 10.31557/APJCP.2020.21.7.1851.